| Business Summary | | Draxis
Health
Inc.
is
a
diversified
specialty
pharmaceutical
company
with
operations
in
four
niche
markets:
radiopharmaceuticals
through
DRAXIMAGE
Inc.;
contract
manufacturing
through
DRAXIS
Pharma
Inc.;
Canadian
pharmaceutical
sales
and
marketing
through
DRAXIS
Pharmaceutica,
and
companion
animal
health
through
Deprenyl
Animal
Health,
Inc.
and
its
global
alliance
with
Pfizer
Inc.,
with
respect
to
Anipryl.
The
Company
is
emerging
from
a
transitional
phase
of
its
development
and,
as
of
December
31,
2000,
it
has
been
reliant
on
income
earned
from
Anipryl.
DRAXIMAGE
discovers,
develops,
manufactures
and
markets
diagnostic
imaging
and
therapeutic
radiopharmaceuticals
for
the
global
marketplace.
Its
products
can
be
divided
into
radioactive
products,
which
are
in
a
radioactive
and
ready-to-use
form
when
shipped
to
customers,
and
non-radioactive
products,
which
are
sold
in
lyophilised
(freeze-dried),
non-radioactive
form. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Draxis
Health
Inc.
is
a
diversified
pharmaceutical
company
with
operations
in
three
niche
businesses:
Veterinary,
Radiopharmaceuticals
and
Canadian
Pharmaceutical
Marketing.
For
the
six
months
ended
6/30/01,
revenues
rose
12%
to
$19.7
million.
Net
loss
before
accounting
change
totalled
$2.5
million
vs.
income
of
$401
thousand.
Revenues
reflect
higher
sales
in
the
Manufacturing
and
Companion
Animal
Health
segments.
Loss
reflects
increased
depreciation
and
amortization
costs. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999
Compensation | | Pay | Exer | |
| Brian King Chairman | -- | -- | Martin Barkin, M.D. Pres
and CEO | $545K | $54K | James Doherty Vice
Chairman | -- | -- | Dan Brazier Pres,
Draxis Pharmaceutica | 230K | -- | Raymond Dore Pres,
DRAXIMAGE Inc. | -- | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|